

Ref: FOI/GS/ID 7349

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

29 September 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Melanoma.

*You asked:*

*Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:*

- a. Bevacizumab (Avastin)*
- b. Dacarbazine (DTIC)*
- c. Trametinib (Mekinist)*
- d. Dabrafenib (Tafinlar)*
- e. Ipilimumab (Yervoy)*
- f. Vemurafenib (Zelboraf)*
- g. Nivolumab (Opdivo)*
- h. Nivolumab + Ipilimumab (Opdivo + Yervoy)*
- i. Pembrolizumab (Keytruda)*
- j. Vemurafenib + cobimetinib (Zelboraf + Cotellic)*
- k. Dabrafenib + Trametinib (Tafinlar + Mekinist)*
- l. Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients*
- m. Other active systemic anti-cancer therapy [please state]*
- n. Palliative care only*

*Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:*

- a. Ipilimumab*
- b. Ipilimumab AND Nivolumab*
- c. Nivolumab*
- d. Pembrolizumab*
- e. Dabrafenib AND Trametinib*
- f. Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*

- g. Other active systemic anti-cancer therapy*
- h. Palliative care only*

Trust response:

Q1.

a. 0

b. 0

c. 0

d. 0

e. 3

f. 1

g. 6

h. 6

i. 40

j. 0

k. 30

l. There are 9 patients for these drugs but it is impossible to determine if they are BRAF V600

m. 2

n. 0

No metastatic patients were found on our system but the results below are from patients where the M in TNM is 1

Q2.

a. 1

b. 0

c. 2

d. 4

e. 6

f. 4

g. 1

h. 0